SEC Form 8-K Summary
Filing company: Jupiter Wellness, Inc. The request metadata identifies BONK, Inc., but the filing itself names Jupiter Wellness, Inc. (Nasdaq: JUPW; warrants: JUPWW).
Reporting date: February 1, 2023. This is a current report under Sections 13 or 15(d) of the Exchange Act and does not report quarterly or annual financial results.
Business and Corporate Actions
- Jupiter Wellness appointed Dr. Hector Alila as an additional director effective February 1, 2023.
- Dr. Alila previously served as a Jupiter Wellness director from February 2019 through December 2022.
- His background includes approximately 30 years of scientific, product-development, and biopharmaceutical management experience. He is the founder, president, and chief executive officer of Esperance Pharmaceutical, Inc.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, balance-sheet, or other operating-financial metrics. It also does not provide financial guidance or forecasts.
Material Changes Versus Prior Period
- The material reported change is the appointment of Dr. Alila to the board following his prior service through December 2022.
- No comparable-period financial information or other operating changes are disclosed.
Guidance, Risks, and Unusual Items
- The company furnished a February 1, 2023 press release as Exhibit 99.1, but the press-release text is not included in the provided filing content. Its substantive guidance or commentary cannot be assessed from this text.
- No new risk factors, contingencies, financing transactions, compensation terms, or unusual financial items are disclosed in the provided filing.
- The company is identified as an emerging growth company.
Investor Verification Points
- Verify the correct issuer: the filing is for Jupiter Wellness, Inc., not BONK, Inc.
- Review Exhibit 99.1 for the contents of the referenced press release and any related outlook or announcements.
- Confirm Dr. Alila’s board role, committee assignments, and any related compensation or arrangements in subsequent filings.
- Use the company’s latest periodic filing to evaluate financial performance, liquidity, debt, and capital needs, because this 8-K contains no such metrics.